ClinicalTrials.gg
CompletedNCT07445646Updated Oct 23, 2026

Efficacy of Different Modalities on Management of Renal Hard Stones

An interventional study of Lithotripsy using Flexible ureteroscope and Extracorporeal shock wave lithotripsy (ESWL) in Urolithiasis and Stone, Kidney, sponsored by Kafrelsheikh University. Completed at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Primary conditionKidney CalculiRegistry: UrolithiasisReclassifiedWhy we changed it
Registry
Urolithiasis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Kidney Calculi
Why
  1. The study's listed conditions name Kidney Calculi, a narrower term within Urolithiasis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Kafrelsheikh University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 years after the study started (first participant enrolled Feb 2023, registered Feb 2026).
Updated Oct 23, 2026Start date movedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 57 studies in Kidney Calculi with a site in Egypt — 21 open to participants now, 23 under way, none of them phase 3. Kidney Calculi · Egypt.

Enrollment
2nd of 52
300 · median 100
Started
2023
with 5 others
No phase
49 of 57
20 open now
Registered
47th of 57
by date

Among the 57 studies in Kidney Calculi with a site in Egypt, this one is the 2nd largest by enrollment of the 52 interventional ones that give a count, is one of 6 that started in 2023, is one of 49 with no phase, and was the 47th registered.

Kidney Calculi

510 studies on the registry are indexed under Kidney Calculi; 147 are open to participants now.

Browse Kidney Calculi studies →

Open to participants now

21 of the 57 studies in Kidney Calculi with a site in Egypt are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 88 Kidney Calculi studies recruiting now, 48 (55%) set no upper age limit and 23 (26%) stop at 75 or younger; 6 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Kidney Calculi with a site in Egypt, or all of them as a file.
02

Study summary

The study has been conducted in Urology department at Kafrelsheikh University Hospital between Feburary 2021 to December 2023. informed consent was taken from eligible patients and were randomized into three groups, Group A :Flexible ureteroscope (F-URS) group underwent holmium laser lithotripsy using flexible ureteroscopy (Boston® scientific (lithovue) while, Group B : extracorporeal shock wave lithotripsy (ESWL) group underwent electromagnetic extracorporeal shock wave lithotripsy (STORZ® MEDICAL Modulith SLX-F2 FD21, Germany) .Group C : Mini perc group underwent holmium laser lithotripsy using Karl® Storz MIP set.

03

Conditions studied

  • Urolithiasis
  • Stone, Kidney

Browse trials for

04

In context

Kidney Calculi Reclassified

510 studies on the registry are indexed under Kidney Calculi; 147 are open to participants now.

This study's enrollment of 300 is above the median of 86 across 392 interventional studies indexed under Kidney Calculi.

Browse Kidney Calculi studies →

Lead sponsor

Kafrelsheikh University is the lead sponsor of 305 studies on the registry; 122 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Compared within Kidney Calculi, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Urolithiasis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient older than 18 years.
  • single renal stone.
  • medium sized Stone up to 2.0 cm .
  • Do novo
  • Stone in plevicalyceal except lower calyceal stone
  • Hard stone

Exclusion criteria

Exclusion Criteria:

  • multiple renal stones
  • Stone in lower calyceal stone
  • stone size > 2 cm
  • age group \< 18
  • solitary kidney
  • Patients with > 40 kg/m2
  • bleeding disorders
  • anatomical renal abnormalities
  • Obstruction distal to the stone.
  • Musculoskeletal deformities
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (actual)

Study arms

  • Active comparator
    Group A :Flexible ureteroscope group

    Flexible ureteroscope (F-URS) group underwent holmium laser lithotripsy using flexible ureteroscopy (Boston® scientific (lithovue)

    Procedure: Lithotripsy using Flexible ureteroscope

  • Active comparator
    Group B : extracorporeal shock wave lithotripsy (ESWL) group

    extracorporeal shock wave lithotripsy (ESWL) group underwent electromagnetic extracorporeal shock wave lithotripsy (STORZ® MEDICAL Modulith SLX-F2 FD21, Germany)

    Procedure: Extracorporeal shock wave lithotripsy (ESWL)

  • Active comparator
    Group C : Mini perc group

    Mini perc group underwent holmium laser lithotripsy using Karl® Storz MIP set.

    Procedure: holmium laser lithotripsy using Karl® Storz MIP

Interventions

  • ProcedureLithotripsy using Flexible ureteroscope

    using Flexible ureteroscope and holmium laser lithotripsy to get high stone clearance rate

  • ProcedureExtracorporeal shock wave lithotripsy (ESWL)

    using extracorporeal shock wave lithotripsy (ESWL) to get high stone clearance rate

  • Procedureholmium laser lithotripsy using Karl® Storz MIP

    using holmium laser lithotripsy using Karl® Storz MIP set to get high stone clearance rate

07

What researchers measure

Primary outcomes

  1. stone free rate

    no stone residual fragments or asymptomatic insignificant residual fragments less than or equal to 4 mm during patients follow up two weeks.

    Time frame: two weeks from primary procedure

Secondary outcomes

  1. ssess operative time

    assess operative time.in minutes

    Time frame: during the procedure

  2. Radiation time

    Time of patient exposure for radiation in minutes

    Time frame: during the procedure

  3. Post operative complication

    Complication may occur post operative complication like fever, sever pain

    Time frame: Up to 48 hours

08

Study locations

1 site
  • Elsayed Abdelhalim
    Zagazig, Zagazig 44749, Egypt
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in Dec 2025, 34 months.

Of 183 non-industry interventional studies with no phase under Kidney Calculi, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 54. This study's 34 months is close to that.

Counting every sponsor, half of 199 studies reached it within 26 months; a quarter within 12 and three quarters within 51.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: start Feb 2021 → Feb 2023, primary completion Dec 2023 → Dec 2025 and completion Dec 2023 → Dec 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2026
First posted
Mar 3, 2026
StartActual
Feb 1, 2023was Feb 2021
Primary completionActual
Dec 30, 2025was Dec 2023
CompletionActual
Dec 30, 2025was Dec 2023
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Elsayed Abdelhalim · Zagazig, Egypt
Show 1 removed
  • Elsayed Abdelhalim · Zagazig, Egypt
Oct 23, 2026
Start date
Feb 1, 2021→Feb 1, 2023
Oct 23, 2026
Primary completion
Dec 30, 2023→Dec 30, 2025
Oct 23, 2026
Study completion
Dec 30, 2023→Dec 30, 2025
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    1 site added, 1 site removed
    Show site
    • Elsayed Abdelhalim · Zagazig, Egypt
    Show 1 removed
    • Elsayed Abdelhalim · Zagazig, Egypt
    Start date Feb 1, 2021→Feb 1, 2023
    Primary completion Dec 30, 2023→Dec 30, 2025
    Study completion Dec 30, 2023→Dec 30, 2025
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07445646
Responsible party
Elsayed Abdelhalim Elsayed (assistant lecturer of urology, Kafrelsheikh University) — Principal investigator
First posted
Mar 3, 2026
Start date
Feb 1, 2023
Primary completion
Dec 30, 2025
Completion
Dec 30, 2025
Last update
Oct 23, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion